Advanced search
Publication Cover
OncoImmunology Volume 2, 2013 - Issue 9
Submit an article Journal homepage
713
Views
11
CrossRef citations to date
0
Altmetric
Author's View

Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4+ and CD8+ T cells

Yusuke Tomita Department of Immunogenetics, Graduate School of Medical Sciences; Kumamoto University; Kumamoto, Japan; Department of Respiratory Medicine; Graduate School of Medical Sciences; Kumamoto University; Kumamoto, Japan
&
Yasuharu Nishimura Department of Immunogenetics, Graduate School of Medical Sciences; Kumamoto University; Kumamoto, JapanCorrespondence[email protected]
Article: e25801 | Received 16 Jul 2013, Accepted 18 Jul 2013, Published online: 29 Jul 2013

References

  • Dobrzanski MJ. Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy. Frontiers in oncology 2013; 3:63. PMID:23533029; http://dx.doi.org/10.3389/fonc.2013.00063.
  • Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008; 8:351 - 60; http://dx.doi.org/10.1038/nrc2373; PMID: 18418403
  • Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, et al. Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer. Br J Cancer 2011; 104:300 - 7; http://dx.doi.org/10.1038/sj.bjc.6606052; PMID: 21179034
  • Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, et al. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers. Clin Cancer Res 2008; 14:6487 - 95; http://dx.doi.org/10.1158/1078-0432.CCR-08-1086; PMID: 18927288
  • Harao M, Hirata S, Irie A, Senju S, Nakatsura T, Komori H, et al. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL. Int J Cancer 2008; 123:2616 - 25; http://dx.doi.org/10.1002/ijc.23823; PMID: 18770861
  • Kono K, Iinuma H, Akutsu Y, Tanaka H, Hayashi N, Uchikado Y, et al. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med 2012; 10:141; http://dx.doi.org/10.1186/1479-5876-10-141; PMID: 22776426
  • Tomita Y, Yuno A, Tsukamoto H, Senju S, Kuroda Y, Hirayama M, et al. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor. [Epub ahead of print.] Clin Cancer Res 2013; In press http://dx.doi.org/10.1158/1078-0432.CCR-13-0197; PMID: 23714729
  • Tomita Y, Yuno A, Tsukamoto H, Senju S, Yoshimura S, Osawa R, et al. Identification of CDCA1 long peptides bearing both CD4+ and CD8+ T-cell epitopes: CDCA1-specific CD4+ T-cell immunity in cancer patients. Int. J. Cancer 2013 in press PMID: http://dx.doi.org/10.1002/ijc.28376
  • Aarntzen EH, De Vries IJ, Lesterhuis WJ, Schuurhuis D, Jacobs JF, Bol K, et al. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res 2013; 73:19 - 29; http://dx.doi.org/10.1158/0008-5472.CAN-12-1127; PMID: 23087058
  • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252 - 64; http://dx.doi.org/10.1038/nrc3239; PMID: 22437870

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.